Silvia Reverté-Villarroya

Prof. Dr. Silvia Reverté-Villarroya

Universitat Rovira i Virgili, Tarragona, Catalonia, Spain
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2013 in The Lancet
Verified
Journal Article
Open access
SGSPS3 Study Group
SPS3 Study Group
OBO R Benavente
O R Benavente
CCC S Coffey
C S Coffey
RCR Conwit
R Conwit
RHR G Hart
R G Hart
Silvia Reverté-VillarroyaSilvia Reverté-Villarroya
Silvia Reverté-Villarroya
Lowering of blood pressure prevents stroke but optimum target levels to prevent recurrent stroke are unknown. We investigated the effects of different blood-pressure targets on the rate of recurrent stroke in patients with recent lacunar stroke. In this randomised open-label trial, eligible patients lived in North America, Latin America, and Spain and had recent, MRI-defined symptomatic lacunar infarctions. Patients were recruited between March, 2003, and April, 2011, and randomly assigned, according to a two-by-two multifactorial design, to a systolic-blood-pressure target of 130-149 mm Hg or less than 130 mm Hg. The primary endpoint was reduction in all stroke (including ischaemic strokes and intracranial haemorrhages). Analysis was done by intention to treat. This study is registered with ClinicalTrials.gov, number NCT 00059306. 3020 enrolled patients, 1519 in the higher-target group and 1501 in the lower-target group, were followed up for a mean of 3·7 (SD 2·0) years. Mean age was 63 (SD 11) years. After 1 year, mean systolic blood pressure was 138 mm Hg (95% CI 137-139) in the higher-target group and 127 mm Hg (95% CI 126-128) in the lower-target group. Non-significant rate reductions were seen for all stroke (hazard ratio 0·81, 95% CI 0·64-1·03, p=0·08), disabling or fatal stroke (0·81, 0·53-1·23, p=0·32), and the composite outcome of myocardial infarction or vascular death (0·84, 0·68-1·04, p=0·32) with the lower target. The rate of intracerebral haemorrhage was reduced significantly (0·37, 0·15-0·95, p=0·03). Treatment-related serious adverse events were infrequent. Although the reduction in stroke was not significant, our results support that in patients with recent lacunar stroke, the use of a systolic-blood-pressure target of less than 130 mm Hg is likely to be beneficial. National Institutes of Health-National Institute of Neurological Disorders and Stroke (NIH-NINDS).

1 September 2017 in Stroke
Verified
Journal Article
Closed access
PDF file
ABAlejandro Bustamante
Alejandro Bustamante
ELElena López-Cancio
Elena López-Cancio
SPSara Pich
Sara Pich
APAnna Penalba
Anna Penalba
DGDolors Giralt
Dolors Giralt
JMJoan Montaner
Joan Montaner
Background and Purpose—: Stroke diagnosis could be challenging in the acute phase. We aimed to develop a blood-based diagnostic tool to differentiate between real strokes and stroke mimics and between ischemic and hemorrhagic strokes in the hyperacute phase. Methods—: The Stroke-Chip was a prospective, observational, multicenter study, conducted at 6 Stroke Centers in Catalonia. Consecutive patients with suspected stroke were enrolled within the first 6 hours after symptom onset, and blood samples were drawn immediately after admission. A 21-biomarker panel selected among previous results and from the literature was measured by immunoassays. Outcomes were differentiation between real strokes and stroke mimics and between ischemic and hemorrhagic strokes. Predictive models were developed by combining biomarkers and clinical variables in logistic regression models. Accuracy was evaluated with receiver operating characteristic curves. Results—: From August 2012 to December 2013, 1308 patients were included (71.9% ischemic, 14.8% stroke mimics, and 13.3% hemorrhagic). For stroke versus stroke mimics comparison, no biomarker resulted included in the logistic regression model, but it was only integrated by clinical variables, with a predictive accuracy of 80.8%. For ischemic versus hemorrhagic strokes comparison, NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) >4.9 (odds ratio, 2.40; 95% confidence interval, 1.55–3.71; P 4.7 (odds ratio, 2.02; 95% confidence interval, 1.19–3.45; P =0.010), together with age, sex, blood pressure, stroke severity, atrial fibrillation, and hypertension, were included in the model. Predictive accuracy was 80.6%. Conclusions—: The studied biomarkers were not sufficient for an accurate differential diagnosis of stroke in the hyperacute setting. Additional discovery of new biomarkers and improvement on laboratory techniques seem necessary for achieving a molecular diagnosis of stroke.

1 September 2019 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
DGDiego Santos García
Diego Santos García
TFT. de Deus Fonticoba
T. de Deus Fonticoba
ECE. Suárez Castro
E. Suárez Castro
CBC. Borrué
C. Borrué
MMM. Mata
M. Mata
VIVillar
Villar

1 April 2010 in Stroke
Verified
Journal Article
Closed access
NONatalia PérEz de la Ossa
Natalia PérEz de la Ossa
Tomas SobrinoTomas Sobrino
Tomas Sobrino
YSYolanda Silva
Yolanda Silva
MBMiguel Blanco
Miguel Blanco
MMMonica Millán
Monica Millán
ADAntoni DávAlos
Antoni DávAlos
Background and Purpose— Iron plays a detrimental role after experimental intracerebral hemorrhage (ICH). This study investigates whether high-serum ferritin levels are associated with poor outcome in patients with ICH. Methods— We studied 92 consecutive patients with primary hemispheric ICH within the first 12 hours from onset of symptoms (median, 3.3 hours). National Institute of Health Stroke Scale score, ICH, and peripheral edema volumes were measured at admission, 72 hours, and 7 days. Serum levels of ferritin and biomarkers of the inflammatory response were determined. The adjusted effect of ferritin on the full range of Rankin scale was analyzed by a general linear model. Results— Fifty-one patients (55.4%) had poor outcome (Rankin score >2). Older age, higher stroke severity, larger hematoma volume, intraventricular extension, mass effect, and higher IL-6 and ferritin levels at baseline (270.6 [SD 81.4] vs 74.6 [SD 43.4] ng/mL; P <0.001) were associated with poor outcome. The higher the ferritin quartile, the worse the Rankin score. For every ferritin quartile, the Rankin score increased by a mean of 1.4 points (95% CI, 1.04–1.69) after adjusting for prognostic variables. Ferritin levels remained stable for 72 hours and did not correlate with acute phase reactants. Conclusions— High-serum ferritin levels at admission are independently associated with poor outcome in patients with ICH. These findings may suggest a neurotoxic effect of increased body iron stores in patients with hemorrhagic stroke.

1 August 2003 in Journal of Chromatography A
Verified
Journal Article
Closed access
Silvia Reverté-VillarroyaSilvia Reverté-Villarroya
Silvia Reverté-Villarroya
FBFrancesc Borrull
Francesc Borrull
EPEva Pocurull
Eva Pocurull
RMRosa Maria Marcé
Rosa Maria Marcé

1 March 2012 in Atherosclerosis
Verified
Journal Article
Closed access
ELElena lópez-Cancio
Elena lópez-Cancio
LDL. Dorado
L. Dorado
MMM. Millán
M. Millán
Silvia Reverté-VillarroyaSilvia Reverté-Villarroya
Silvia Reverté-Villarroya
ASA. Suñol
A. Suñol
JAJ.F. Arenillas
J.F. Arenillas